Cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy improve survival of patients with peritoneal carcinomato-sis from colorectal cancer:a retrospective case-control study
10.3969/j.issn.1000-8179.20130155
- VernacularTitle:细胞减灭术加腹腔热灌注化疗治疗结直肠癌腹膜转移癌病例对照研究*
- Author:
Chaoqun HUANG
;
Yunfeng ZHOU
;
Conghua XIE
;
Xiaojun YANG
;
Fulin CHENG
;
Bin XIONG
;
Guoliang YANG
;
Yan LI
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
cytoreductive surgery;
hyperthermic intra-peritoneal chemotherapy;
peritoneal carcinomatosis
- From:
Chinese Journal of Clinical Oncology
2013;(16):979-983
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of cytoreductive surgery (CRS) in conjunction with hyperthermic intra-peritoneal chemotherapy (HIPEC) for treating patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC). Methods:A total of 62 CRC patients with complication of PC were divided into the CRS group, namely, Group One (n=29, CRS and systemic adju-vant chemotherapy) and the CRS+HIPEC group, namely, Group Two (n=33, CRS+HIPEC). The primary end point of the study was overall survival (OS) and the secondary end point was serious adverse events (SAE). Results:Patients' clinicopathologic characteris-tics, peritoneal carcinomatosis index, and completeness of cytoreduction therapy were well balanced and comparable between the two groups. The median follow-up was 41.9 mo (6.5 mo to 110.0 mo) in Group One and 32.0 mo (10.5 mo to 95.9 mo) in Group Two. The median OS was 8.5 mo (95%CI:4.9 mo to 12.1 mo) in Group One and 14.5 mo (95%CI:11.9 mo to 17.1 mo) in Group Two (P=0.007). Within 30 days after the surgery, SAE occurred in 3 of the 29 patients in Group One, and 9 of the 33 patients in Group Two (P=0.126). Multivariate analysis revealed that HIPEC, CC0-1 score, and chemotherapy over six cycles were the independent factors for OS improvement. Conclusion:The CRS+HIPEC method improves the OS of patients with PC from CRC, suggesting an acceptable safety.
